Rivaroxaban tablets, film-coated, 15 mg; Rivaroxaban tablets, film-coated, 20 mg; Alteplase lyophilisate for solution for infusion, 50 mg vial. DK 021 2015 33600000-6 Pharmaceutical products.

This tender is for the procurement of specific pharmaceutical products, namely Rivaroxaban tablets in 15 mg and 20 mg strengths, both film-coated, and Alteplase lyophilisate for solution for infusion in a 50 mg vial. The overall category for this procurement is 'Pharmaceutical products' under the CPV code 33600000-6. The listed items, Rivaroxaban and Alteplase, are critical medications. Rivaroxaban is an anticoagulant used to prevent and treat blood clots, while Alteplase is a thrombolytic agent used to break down existing blood clots in conditions such as heart attack and stroke. The tender explicitly states a restriction: the supplied goods must not originate from the Russian Federation, the Republic of Belarus, or the Islamic Republic of Iran. The procuring entity is the Communal Non-Profit Enterprise "Starokostiantyniv Multidisciplinary Hospital" of the Starokostiantyniv City Council. This procurement aims to ensure the availability of essential medicines for patient treatment within the hospital, focusing on cardiovascular and thrombotic conditions, while adhering to specific origin restrictions for the supplied pharmaceuticals.

This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals and General Supplies. Located in Ukraine, Europe, this opportunity is open to firms and consortiums, with an estimated budget of UAH 2.6 million.

Published through ProZorro Ukraine, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.